PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CALX vs. MNPR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CALX and MNPR is 0.11, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

CALX vs. MNPR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Calix, Inc. (CALX) and Monopar Therapeutics Inc. (MNPR). The values are adjusted to include any dividend payments, if applicable.

0.00%500.00%1,000.00%1,500.00%2,000.00%SeptemberOctoberNovemberDecember2025February
6.68%
1,607.69%
CALX
MNPR

Key characteristics

Sharpe Ratio

CALX:

0.37

MNPR:

3.96

Sortino Ratio

CALX:

0.83

MNPR:

9.66

Omega Ratio

CALX:

1.10

MNPR:

2.33

Calmar Ratio

CALX:

0.22

MNPR:

25.51

Martin Ratio

CALX:

1.14

MNPR:

59.82

Ulcer Index

CALX:

12.48%

MNPR:

42.10%

Daily Std Dev

CALX:

38.66%

MNPR:

637.78%

Max Drawdown

CALX:

-80.95%

MNPR:

-98.93%

Current Drawdown

CALX:

-50.44%

MNPR:

-67.32%

Fundamentals

Market Cap

CALX:

$2.63B

MNPR:

$269.24M

EPS

CALX:

-$0.45

MNPR:

-$1.98

Total Revenue (TTM)

CALX:

$625.39M

MNPR:

$0.00

EBITDA (TTM)

CALX:

-$9.48M

MNPR:

-$1.58B

Returns By Period

In the year-to-date period, CALX achieves a 13.65% return, which is significantly lower than MNPR's 100.55% return.


CALX

YTD

13.65%

1M

4.54%

6M

5.20%

1Y

16.83%

5Y*

30.54%

10Y*

17.10%

MNPR

YTD

100.55%

1M

54.59%

6M

1,679.03%

1Y

2,472.59%

5Y*

-4.17%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CALX vs. MNPR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CALX
The Risk-Adjusted Performance Rank of CALX is 5555
Overall Rank
The Sharpe Ratio Rank of CALX is 5858
Sharpe Ratio Rank
The Sortino Ratio Rank of CALX is 5353
Sortino Ratio Rank
The Omega Ratio Rank of CALX is 5050
Omega Ratio Rank
The Calmar Ratio Rank of CALX is 5656
Calmar Ratio Rank
The Martin Ratio Rank of CALX is 5858
Martin Ratio Rank

MNPR
The Risk-Adjusted Performance Rank of MNPR is 9999
Overall Rank
The Sharpe Ratio Rank of MNPR is 9999
Sharpe Ratio Rank
The Sortino Ratio Rank of MNPR is 9999
Sortino Ratio Rank
The Omega Ratio Rank of MNPR is 9999
Omega Ratio Rank
The Calmar Ratio Rank of MNPR is 100100
Calmar Ratio Rank
The Martin Ratio Rank of MNPR is 100100
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CALX vs. MNPR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Calix, Inc. (CALX) and Monopar Therapeutics Inc. (MNPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CALX, currently valued at 0.37, compared to the broader market-2.000.002.004.000.373.96
The chart of Sortino ratio for CALX, currently valued at 0.83, compared to the broader market-4.00-2.000.002.004.006.000.839.66
The chart of Omega ratio for CALX, currently valued at 1.10, compared to the broader market0.501.001.502.001.102.33
The chart of Calmar ratio for CALX, currently valued at 0.22, compared to the broader market0.002.004.006.000.2225.51
The chart of Martin ratio for CALX, currently valued at 1.14, compared to the broader market0.0010.0020.0030.001.1459.82
CALX
MNPR

The current CALX Sharpe Ratio is 0.37, which is lower than the MNPR Sharpe Ratio of 3.96. The chart below compares the historical Sharpe Ratios of CALX and MNPR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00SeptemberOctoberNovemberDecember2025February
0.37
3.96
CALX
MNPR

Dividends

CALX vs. MNPR - Dividend Comparison

Neither CALX nor MNPR has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CALX vs. MNPR - Drawdown Comparison

The maximum CALX drawdown since its inception was -80.95%, smaller than the maximum MNPR drawdown of -98.93%. Use the drawdown chart below to compare losses from any high point for CALX and MNPR. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%SeptemberOctoberNovemberDecember2025February
-50.44%
-67.32%
CALX
MNPR

Volatility

CALX vs. MNPR - Volatility Comparison

The current volatility for Calix, Inc. (CALX) is 12.75%, while Monopar Therapeutics Inc. (MNPR) has a volatility of 43.74%. This indicates that CALX experiences smaller price fluctuations and is considered to be less risky than MNPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%50.00%100.00%150.00%200.00%SeptemberOctoberNovemberDecember2025February
12.75%
43.74%
CALX
MNPR

Financials

CALX vs. MNPR - Financials Comparison

This section allows you to compare key financial metrics between Calix, Inc. and Monopar Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab